|Videos|April 9, 2013
Episode 13- Current Developments of Pharmacotherapeutic Spending
Advertisement
Episodes in this series
During this segment, David Calabrese, RPh, MHP, explores the current trends of pharmacotherapeutic spending for the treatment of chronic conditions.
Mr Calabrese explains that from a research and developmental stage, there has been a stronger trend toward investing within the specialty market, rather than on traditional products.
Over 30 new products have been approved in the United States over the past year, and this number is expected to continue to grow annually. For this reason, investors seem more interested in supporting today’s higher-cost, complex therapies rather than traditional products for the treatment of chronic conditions.
Advertisement
Related to this article
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5